Search Results
Results found for "Glaxo Inc"
- Advantages of Fluorescent Probes in GPCR Assays
limitations, especially safety concerns, low temporal resolution and the need for specialized facilities including Our portfolio also includes all kinds of dyes, such as pharmacophores conjugated to near-infrared fluorophores Once the cells are ready, the fluorescent ligand is added, and the cells are incubated with it for a After incubation, cells are observed using a confocal microscope. Celtarys’ protocol section includes detailed protocols for diverse applications and fluorescent ligands
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Wendy Young’s talk, during session 3 on day 2, was also incredible.
- Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
Cannabinoids have the potential to treat a variety of diseases, including neurological and metabolic The curves were obtained using 100nM of probe and increasing concentrations of Δ9-THC, Δ9-THCA and Δ9
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
when talking about SCRAs (Synthetic Cannabinoid Agonists), as one of the series developed by Pfizer, including Tag-Lite® competition binding curves were obtained by using 100 nM of CELT-335 and increasing concentrations Competition binding curves were obtained through Tag-lite® technology using 10 nM of CELT-335 and increasing For further validation, a larger range of compounds will be tested, including screening chemical libraries
- Radioligands vs. Fluorescent Ligands: Binding Assays
While their high specificity and extensive experience working with them, other drawbacks include radiation
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
temporary therapeutic effects.[3,4] Since dopaminergic signaling is very complex, there’s a need to increase FA of 3 nM (orange squares) or 0.5 nM (blue circles) CELT-419 were measured after 2 h incubation with Change in FA level was measured after incubation of 0.5 nM CELT-419, 1 μL BBV/well (CD3R = 0.7 nM), and HEK293-D3R cells in DMEM medium with added 9% FBS and antibiotic antimycotic solution were incubated As the next step, the cells were incubated with different concentrations of CELT-419 to determine its
- Conjugation Strategies for Probe Development
It’s reversible under non-reducing conditions. [ 4]   Other strategies include click chemistry,  more There’s no need for any catalysts; all reagents will be incorporated in the structure of the final compound
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
Learn to tie your program's progress directly to your funding runway, incorporating crucial early commercial
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Career opportunities:  A curated list of new positions, including a Research Associate, a Senior Research misinterpreting your data by understanding how slow-offset kinetics can mimic classical patterns, leading to incorrect FAQ 🔹 What’s included?
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Each subscription includes: Weekly deep dives from Dr.
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
residence time—not potency—predicts therapeutic coverage ✅ Insight into cryptic intracellular GPCR sites, including And intracellular targets, including allosteric sites unreachable from the extracellular side, become
- Your GPCR Program Decisions Depend on Good Data Interpretation
Ingo Hartung : State-of-the-art design of small molecule drugs, including PROTACs Dr. FAQ: What’s Included, Who It’s For, Why Now What’s included?
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
GPCR Premium 🔹 What’s included?
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
GPCR Premium What’s included? Â
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
alerts, job opportunities, and insider commentary—all designed to help you move faster and smarter in an increasingly GPCR Premium gives you an edge in a fast-moving field. 🔹 Premium Membership FAQ 🔹 What’s included?
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
He was tasked with building an in vitro pharmacology group from scratch , including infrastructure, hiring
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
studying GPCRs—arguably the most important drug targets in pharmacology—has been wrong… or at least, incomplete
- Signals in Motion: Pain, Metabolism & Terry’s Corner
Meanwhile, incretin and amylin-based therapies are reshaping the obesity drug landscape.
- Pharmacology Isn't What You Think—It's So Much More
Whether you're heading into your first assay or trying to make sense of inconsistent data, Terry gives
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
A tenfold increase in methadone efficacy using PAMs.
- Science Needs Rigor, But Also Joy
But every day also includes squirrel-themed trivia and impromptu debates about obscure molecules.
- Ben Clements on Rescuing Opioids with GPCR Modulators
Redefining Opioid Pharmacology Ben and his colleagues discovered that PAMs can dramatically increase In fact, one of their recent neuroma pain studies showed a tenfold increase in methadone potency. That’s not an incremental advance; that’s a potential paradigm shift. Using PAMs, his team aims to re-sensitize these conditions to opioids without increasing toxicity.
- Mapping Motion: Intermediate States, Deorphanization & Discovery
This course is included with your Premium membership. Â Access the Course Dr. These on-demand sessions are included with your Premium membership. Â
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
conformational dynamics of the receptor rather than a lowered sensitivity for detecting weaker interactions, as increasing A standard format of GPCR biosensors incorporates a luminescent tag on the G protein Gα subunit and Gβγ Similar effects of varying intensity were observed for several other GPCRs, including the β2-adrenergic Additionally, as mini-G proteins are increasingly implemented in structural determinations of GPCRs and
- 🎄 Have Yourself a Merry Little GPCRmas! ❄ Dec 9 - 15, 2024
GPCR Team This Week’s Highlights: Congratulations to Andrew Tobin for an incredible week filled with prestigious events, including receiving the British Pharmacological Society Vane Medal and switching
- GPCR News Flash! Top Updates You Can't-Miss! + University CheatSheet is finally available! âť„ Dec 2 - 8, 2024
As a Premium Member, you gain exclusive access to this incredible treasure trove we've amassed over the Daridorexant in South Korea Septerna Touches New High, To Report SEP-786 Data In Mid-2025 How GPCR agonists, including
- Reflections on My PhD Journey: Lessons Learned
Procrastination may seem tempting, but tackling your work incrementally will save time and reduce stress
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
exceptional services to achieve our goal of leading a vibrant and healthy life , all thanks to the incredible Embrace the excitement of supporting us and unlocking incredible perks such as: Dr.
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
This strategic decision to limit free content is essential as we need to increase revenue to support





























